Viewing PEGBIO CO-B (02565) merely as a company with a single GLP-1 product may no longer be sufficient. The 2026 interim report warrants a fresh look from the capital markets, not for an increased pipeline count, but for the company's clear evolution from "one product, Weipena Peptide" into a portfolio of next-generation metabolic assets. The most significant source of new expectations lies with PB-2312, a preclinical candidate that has debuted by positioning retatrutide and efruxifermin directly within its comparative framework.
Weipena Peptide Begins to Deliver: Answering the "Can It Become a Drug" Question
Weipena Peptide injection (brand name: Paidakang®, development code PB-119) received market approval in November 2025. In March 2026, the company entered a commercial partnership with Tengrui Pharma for mainland China, and received an initial milestone payment of approximately HKD 61 million during the reporting period. Following the reporting period, Paidakang® has seen its first commercial prescriptions filled at multiple medical institutions, and the conditions for the second payment of approximately HKD 49 million have all been met. Additionally, Weipena Peptide has passed the preliminary formal review for the 2026 National Reimbursement Drug List adjustment. For PEGBIO, the significance of Weipena Peptide now goes beyond being just another GLP-1; it demonstrates the company has fully navigated the journey from drug discovery, clinical development, and regulatory filing to commercial launch. The market's next key question becomes: can PEGBIO continue to create differentiated drugs?
Oral Delivery is Just the Appetizer; Real Valuation Upside Comes from Next-Gen Assets
Following the reporting period, PEGBIO announced collaborations with Rani Therapeutics and Lexaria Bioscience focused on oral delivery. The former explores the RaniPill® platform for oral biologic delivery, while the latter utilizes DehydraTECH™ technology for formulation and pharmacokinetic studies. These partnerships may lead the market to label PEGBIO as an "oral GLP-1" player. However, a deeper look into the interim report reveals the company is simultaneously pursuing three distinct next-generation metabolic strategies: ultra-long-acting RNA expression, fat reduction with muscle preservation, and weight loss combined with MASH treatment.
CR059: Beyond the "Once-Weekly Injection" Paradigm
CR059 uses circular RNA technology to achieve sustained in vivo expression of GLP-1-like therapeutic molecules. The interim report shows that the investigator-initiated trial (IIT) for CR059 has been completed, with the first-in-human study reaching a staged milestone. In non-human primate studies, a single dose resulted in sustained expression for over eight weeks, with these findings accepted as a Late-Breaking Abstract at ADA 2026 and for an oral presentation at EASD 2026. While "over eight weeks" remains a non-human primate result and cannot be directly extrapolated to human dosing intervals, the broader vision is more compelling than just the duration itself. This approach aims to shift from extending peptide half-life to enabling continuous expression of therapeutic proteins in the body. If successfully validated in humans, it could redefine the competitive landscape.
APGP6: The Next Battle in Weight Loss Isn't Just About the Number
APGP6 focuses on the quality of weight loss. Its development goal is to reduce fat mass while improving or preserving lean body mass and muscle function. Preclinical studies have shown positive results across metrics such as weight reduction, fat loss, lean mass preservation, and improved muscle function. More intriguingly, the company has also observed positive signals in preclinical research for improved cardiac function, inhibition of ventricular remodeling, and reduced fibrosis. These findings extend APGP6's potential from simple "fat loss with muscle preservation" to broader body composition management and cardiometabolic health.
PB-2312: A First Systematic Debut Directly Challenging Two Benchmark Candidates
The element adding an unexpected layer to this interim report is PB-2312. This is not a mature project progressing on a predictable timeline, but a new asset that has largely been absent from market valuation discussions. Crucially, its systematic disclosure in this report places retatrutide and efruxifermin directly within the same DIO-MASH model. PB-2312 is a multi-target candidate for metabolic diseases, aiming to reduce body weight and fat content while improving overall metabolic health, with potential applications in weight management, MASH, and other metabolic conditions. In essence, it is designed from the outset to address two questions simultaneously: can it achieve robust weight loss, and can it concurrently improve liver metabolic damage?
Under identical study conditions, PB-2312 demonstrated significant and sustained weight reduction, with a greater weight-loss effect than comparator candidates including retatrutide and efruxifermin, accompanied by a consistent decrease in food intake. More critically, PB-2312 showed positive improvements in liver histological parameters such as NAS score, steatosis, and inflammation. Its overall liver histological improvement was comparable to efruxifermin and superior to retatrutide. The key takeaway for the capital markets is not simply that one animal metric outperformed another, but that a single asset, upon its first systematic appearance, has established clear benchmarks across both weight loss and MASH: challenging next-generation high-intensity weight loss on one front and benchmarking against a leading MASH candidate on the other. For a preclinical asset, this constitutes a significant new source of expectation gap.
Of course, animal model results cannot be directly translated into human efficacy. PB-2312 cannot yet be prematurely defined as a best-in-class candidate. However, if future clinical trials in humans preserve this dual-dimensional signal, its valuation framework would not be that of just another weight-loss drug, but rather a metabolic asset spanning weight management and MASH with broader indication potential. The company is currently advancing IND-enabling studies for PB-2312, covering efficacy, safety, CMC, and toxicology. For the market, the crucial next step is when this card transitions from a "high-quality preclinical option" to a "clinical asset that can be formally priced."
After CNY 110 Million in R&D Investment, the Market Should Ask: What Has the Money Become?
In the first half of 2026, PEGBIO's R&D expenses increased from approximately CNY 26.29 million in the same period last year to approximately CNY 110 million. The increase in R&D spending alone does not constitute value; what matters is what the investment has ultimately yielded. Based on this interim report, at least three distinct asset logics have emerged: CR059 for ultra-long-acting RNA expression, APGP6 for fat reduction with muscle preservation and body composition management, and PB-2312, which most directly combines weight management and MASH into the product definition of a single candidate. This is why PEGBIO's valuation logic may be shifting from "how much can Weipena Peptide sell" to another question: Weipena Peptide provides commercial certainty, but how much future upside can these next-generation assets contribute?
The Real Re-rating Catalyst: When APGP6 and PB-2312 Enter the Clinic
Today, APGP6 and PB-2312 remain in preclinical or IND-enabling stages, which inherently carries a significant translational discount. However, this also clarifies the value milestones ahead: IND/FPI is the first re-rating event, safety and PK/PD data provide the second layer of validation, and early differentiated proof-of-concept will ultimately determine whether they can join the core asset portfolio. Particularly for PB-2312, if it can retain both weight loss and MASH signals in human trials, the market's pricing for it would not be a linear extrapolation from a single indication but would begin to consider a broader cross-indication metabolic asset framework.
Conclusion: Oral Delivery Garnered Attention, but PEGBIO's Real Addition is a "Second and Third Card"
Weipena Peptide addresses the question of whether PEGBIO can successfully develop and commercialize a drug. CR059, APGP6, and PB-2312 begin to answer a more critical question: can PEGBIO consistently produce differentiated next-generation metabolic assets? Among these, PB-2312, which directly challenged retatrutide and efruxifermin upon its systematic disclosure in this interim report and delivered competitive results in both weight loss and MASH dimensions, is likely the most significant piece of R&D information for creating a new expectation gap. Oral GLP-1 has brought attention, but what may ultimately determine PEGBIO's next valuation phase are these new assets that are not yet fully priced but are already demonstrating clear product logic.
Comments